Contravir: Creating novel treatments for chronic viral infections

Get the Flash Player to see this video.

 

Contravir: Creating novel treatments for chronic viral infections.

Currently there are about 350 million chronic HBV patients worldwide and 786,000 reported HBV-related deaths in 2010. The limited efficacy of current antiviral treatments highlights the need for new therapeutic tools for treating chronic HBV.

During BIO 2015, James Sapirstein, CEO of ContraVir, explained to Fintan Walton, CEO of PharmaVentures, how with their two lead products they plan to tackle this and also post-herpetic neuralgia (PHN).